Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Luigi Naldi and Paolo Gisondi.
Luigi Naldi
Connection Strength
7.291
Paolo Gisondi
  1. Impact of the COVID-19 pandemic on melanoma diagnosis. J Eur Acad Dermatol Venereol. 2021 Nov; 35(11):e714-e715.
    View in: PubMed
    Score: 0.958
  2. Preference for Telemedicine Versus In-Person Visit Among Patients with Psoriasis Receiving Biological Drugs. Dermatol Ther (Heidelb). 2021 Aug; 11(4):1333-1343.
    View in: PubMed
    Score: 0.953
  3. Time of Onset of Selected Skin Lesions Associated with COVID-19: A Systematic Review. Dermatol Ther (Heidelb). 2021 Jun; 11(3):695-705.
    View in: PubMed
    Score: 0.938
  4. The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. Clin Exp Rheumatol. 2021 Sep-Oct; 39(5):1099-1107.
    View in: PubMed
    Score: 0.930
  5. Cutaneous manifestations of SARS-CoV-2 infection: a clinical update. J Eur Acad Dermatol Venereol. 2020 Nov; 34(11):2499-2504.
    View in: PubMed
    Score: 0.893
  6. Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice. J Eur Acad Dermatol Venereol. 2020 Jun; 34(6):1196-1201.
    View in: PubMed
    Score: 0.885
  7. Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence. J Invest Dermatol. 2022 02; 142(2):355-363.e7.
    View in: PubMed
    Score: 0.240
  8. Insights into Sars-CoV-2 vaccination in patients with chronic plaque psoriasis on systemic treatments. J Eur Acad Dermatol Venereol. 2021 Jun; 35(6):e361-e362.
    View in: PubMed
    Score: 0.234
  9. Is SARS-CoV-2 screening test indicated for psoriasis patients candidate to biologic therapy? J Eur Acad Dermatol Venereol. 2021 Jun; 35(6):e355-e357.
    View in: PubMed
    Score: 0.233
  10. Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience. J Allergy Clin Immunol. 2021 Feb; 147(2):558-560.e1.
    View in: PubMed
    Score: 0.228
  11. Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy. Am J Clin Dermatol. 2020 10; 21(5):749-751.
    View in: PubMed
    Score: 0.226
  12. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. Br J Dermatol. 2020 08; 183(2):373-374.
    View in: PubMed
    Score: 0.221
  13. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017 May; 31(5):774-790.
    View in: PubMed
    Score: 0.177
  14. Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. J Eur Acad Dermatol Venereol. 2021 Oct; 35(10):e636-e640.
    View in: PubMed
    Score: 0.060
  15. Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. Br J Dermatol. 2021 07; 185(1):80-90.
    View in: PubMed
    Score: 0.058
  16. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2021 01; 147(1):60-71.
    View in: PubMed
    Score: 0.057
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.